Middle East and North Africa Allergy Diagnostics Market – Industry Trends and Forecast to 2030

Middle East and North Africa Allergy Diagnostics Market Analysis and Size

According to the WHO (World Health Organization), cities house nearly 80% of the world's population, and as a result, air quality has a significant impact on them, particularly in low-income countries. Furthermore, several studies have linked air pollution to allergic rhinitis, asthma, and other disorders, which has increased allergy diagnoses. Although allergies can affect almost every organ in the body and are caused by various external factors, there are a few common themes that should be highlighted in research efforts. As with many other chronic diseases, effective prevention, curative therapy, and accurate, early diagnosis are critical unmet needs.

Data Bridge Market Research analyses that the allergy diagnostics market which is USD 276.32 billion in 2022, is expected to reach USD 558.72 billion by 2030, at a CAGR of 9.2% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Middle East and North Africa Allergy Diagnostics Market Scope and Segmentation

Market Definition

Allergies affect nearly every organ in the body in various ways, resulting in a wide range of symptoms, and thus their manifestations cover a wide range of phenotypes. According to European studies, up to 30% of the population has allergic rhinoconjunctivitis, 20% has asthma, and 15% has allergic skin diseases. Allergies are diagnosed by the primary care provider or an allergist by taking your medical and family history, listening to the symptoms report and performing a physical examination.

Middle East and North Africa Allergy Diagnostics Market Dynamics

Drivers

• Rising prevalence of allergic diseases

The rising prevalence of allergic diseases such as hives, atopic dermatitis, allergic conjunctivitis, and others will drive market growth. For instance, according to an article titled 'Eczema' published by StatPearls in August 2021, the lifetime prevalence of eczema in children is between 15-30% and 2-10% in adults. Furthermore, according to the same source, approximately 50% of patients with severe atopic dermatitis will develop asthma, and 75% will develop allergic rhinitis. These are the certain factors that propel the market growth.

• Increase in the access to health insurance

Large hospitals and diagnostic laboratories have a larger share of this market because of their large capital budgets. Increasing healthcare expenditure as a result of high healthcare service costs is significantly contributing to the growth of the allergy diagnostics market. Furthermore, the governments of several economies are providing reimbursements and healthcare insurance plans to increase consumer flow in the allergy diagnostics market around the world.

Opportunities

• • Use of mHealth in allergy diagnosis

The use of mHealth for rhinitis diagnosis is currently limited, with only a few mHealth tools for allergic rhinitis (AR) diagnosis published in peer-reviewed journals. Recent advancements in integrated biosensors, wireless communication, and power harvesting techniques have resulted in a new breed of point-of-care devices. However, AR is a very common disease. Any diagnostic device connected to a smartphone (For instance, peak nasal inspiratory flow metres or intranasal biosensors) would have to be inexpensive to be affordable.

• Rise in R&D activities

The increasing emphasis of companies on R&D activities to develop novel diagnostic products, tests, or kits to meet high unmet medical needs is impacting market growth significantly. For instance, Omega Diagnostics received approval from the China National Medical Products Administration (NMPA) in November 2020 for Omega's food detective test in China. HYCOR Biomedical and Changsha Haike Biotechnology Co., Ltd. also registered their ALLEOS 2000 allergy testing system in China Hunan Medical Products Administration in August 2020.

Restraints/Challenges

• Premium costs associated with allergy diagnostic instruments

Several allergy diagnostic devices, such as luminometers, blot analyzers, scanners, ELISA analyzers, and immunoassay analyzers, are regularly updated by market participants. Because they have more advanced features and functions, these instruments are more expensive (the price of each instrument varies based on its accuracy, flexibility, and TAT). Immunoassay analyzers, for example, cost between $10,000 and $20,000, while luminometers cost between $3,000 and $14,000. ELISA readers that are semi-automated cost between $2,000 and $5,000, while fully automated analyzers cost over $14,000. Furthermore, operating this equipment incurs additional expenses such as maintenance and insurance, laboratory supervision, and overheads (such as utilities, space, and administration).

This allergy diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the allergy diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Minaris Medical America, Inc. took the place of Hitachi Chemical Diagnostics, Inc. Hitachi intends to strengthen its global position and expand commercial activities in the field of in-vitro diagnostics by unifying the medical business group firms under the Minaris Medical brand. Showa Denko Materials Co., Ltd. owns both companies.
• In 2021, PerkinElmer Inc. agreed to acquire Immunodiagnostic Systems Holdings PLC. As a result of the acquisition, PerkinElmer Inc. will be able to strengthen its position in the ImmunoDiagnostics (IDS) industry. IDS will be acquired by EUROIMMUN Medizinische LABORDIAGNOSTIKA AG, which sells allergy products and services.

Global Middle East and North Africa Allergy Diagnostics Market Scope

The allergy diagnostics market is segmented on the basis of products and services, allergan, test, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products and Services

• Assay Kits
• Consumables
• Instruments
• Immunoassay Analyzers
• ELISA Analyzers
• Luminometers
• Other Instruments
• Services

Allergen

• Inhaled Allergens
• Food Allergens
• Drug Allergens
• Other Allergens

Test

• In Vivo Tests
• Skin Prick Tests
• Patch Tests
• Other In Vivo Tests
• In Vitro Tests

End User

• Diagnostic Laboratories
• Hospital-based Laboratories
• Academic Research Institutes
• Other End Users

Distribution Channel

•  Direct
•  Indirect

Middle East and North Africa Allergy Diagnostics Market Regional Analysis/Insights

The allergy diagnostics market is analyzed and market size insights and trends are provided by country, products and services, allergan, test, end-user and distribution channel as referenced above.

The countries covered in the allergy diagnostics market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Saudi Arabia dominates the allergy diagnostics market because the UAE is the leader in allergy diagnostics manufacturing and exports major component parts required for allergy diagnostics. For example, Omega Diagnostics Group PLC will be the market leader in 2030, with a share of around 26.63%.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The allergy diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for allergy diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the allergy diagnostics market. The data is available for historic period 2011-2021.

Competitive Landscape and Middle East and North Africa Allergy Diagnostics Market Share Analysis

The allergy diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to allergy diagnostics market.

Some of the major players operating in the allergy diagnostics market are:

• Thermo Fisher Scientific Inc. (U.S.)
• Siemens Healthcare GmbH (Germany)
• Danaher (U.S.)
• Omega Diagnostics Group PLC (U.K.)
• BIOMÉRIEUX (France)
• Romer Labs Division Holding (Austria)
• EUROIMMUN Medizinische Labordiagnostika AG (Germany)
• HollisterStier Allergy (U.S.)
• NEOGEN Corporation (U.S.)
• Eurofins Scientific (Luxembourg)
• Minaris Medical America, Inc. (U.S.)
• Stallergenes Greer (U.K.)
• HOB Biotech Group Corp., Ltd. (China)
• HYCOR Biomedical (U.S.)
• R-Biopharm AG (Germany)
• AESKU GROUP GmbH (Germany)
• ACON Laboratories, Inc. (U.S.)
• Lincoln Diagnostics, Inc. (U.S.)
• Astra Biotech GmbH (Germany)
• Erba Group (U.K.)

SKU-50719